122 related articles for article (PubMed ID: 25813472)
1. The amount of injected 177Lu-octreotate strongly influences biodistribution and dosimetry in C57BL/6N mice.
Schüler E; Österlund A; Forssell-Aronsson E
Acta Oncol; 2016; 55(1):68-76. PubMed ID: 25813472
[TBL] [Abstract][Full Text] [Related]
2. Differences in biodistribution between 99mTc-depreotide, 111In-DTPA-octreotide, and 177Lu-DOTA-Tyr3-octreotate in a small cell lung cancer animal model.
Schmitt A; Bernhardt P; Nilsson O; Ahlman H; Kölby L; Forssell-Aronsson E
Cancer Biother Radiopharm; 2005 Apr; 20(2):231-6. PubMed ID: 15869461
[TBL] [Abstract][Full Text] [Related]
3. Diagnostic versus therapeutic doses of [(177)Lu-DOTA-Tyr(3)]-octreotate: uptake and dosimetry in somatostatin receptor-positive tumors and normal organs.
Müller C; Forrer F; Bernard BF; Melis M; Konijnenberg M; Krenning EP; de Jong M
Cancer Biother Radiopharm; 2007 Feb; 22(1):151-9. PubMed ID: 17627424
[TBL] [Abstract][Full Text] [Related]
4. Neuroblastoma xenograft models demonstrate the therapeutic potential of
Romiani A; Spetz J; Shubbar E; Lind DE; Hallberg B; Palmer RH; Forssell-Aronsson E
BMC Cancer; 2021 Aug; 21(1):950. PubMed ID: 34433438
[TBL] [Abstract][Full Text] [Related]
5. Biodistribution and dosimetry of 177Lu-labeled [DOTA0,Tyr3]octreotate in male nude mice with human small cell lung cancer.
Schmitt A; Bernhardt P; Nilsson O; Ahlman H; Kölby L; Schmitt J; Forssel-Aronsson E
Cancer Biother Radiopharm; 2003 Aug; 18(4):593-9. PubMed ID: 14503955
[TBL] [Abstract][Full Text] [Related]
6. A stylized computational model of the rat for organ dosimetry in support of preclinical evaluations of peptide receptor radionuclide therapy with (90)Y, (111)In, or (177)Lu.
Konijnenberg MW; Bijster M; Krenning EP; De Jong M
J Nucl Med; 2004 Jul; 45(7):1260-9. PubMed ID: 15235075
[TBL] [Abstract][Full Text] [Related]
7. Transcriptional response of kidney tissue after 177Lu-octreotate administration in mice.
Schüler E; Rudqvist N; Parris TZ; Langen B; Helou K; Forssell-Aronsson E
Nucl Med Biol; 2014 Mar; 41(3):238-47. PubMed ID: 24434014
[TBL] [Abstract][Full Text] [Related]
8. Dosimetric analysis of patients with gastro entero pancreatic neuroendocrine tumors (NETs) treated with PRCRT (peptide receptor chemo radionuclide therapy) using Lu-177 DOTATATE and capecitabine/temozolomide (CAP/TEM).
Thakral P; Sen I; Pant V; Gupta SK; Dureja S; Kumari J; Kumar S; Un P; Malasani V
Br J Radiol; 2018 Nov; 91(1091):20170172. PubMed ID: 30028180
[TBL] [Abstract][Full Text] [Related]
9. Comparison of [177Lu-DOTA0,Tyr3]-octreotate and [177Lu-DOTA0,Tyr3]-octreotide for receptor-mediated radiation therapy of the xenografted human midgut carcinoid tumor GOT1.
Swärd C; Bernhardt P; Johanson V; Schmitt A; Ahlman H; Stridsberg M; Forssell-Aronsson E; Nilsson O; Kölby L
Cancer Biother Radiopharm; 2008 Feb; 23(1):114-20. PubMed ID: 18298335
[TBL] [Abstract][Full Text] [Related]
10. Comparison of 111In-[DTPA0]Octreotide Versus Non Carrier Added 177Lu- [DOTA0,Tyr3]-Octreotate Efficacy in Patients With GEP-NET Treated Intra-arterially for Liver Metastases.
Limouris GS; Poulantzas V; Trompoukis N; Karfis I; Chondrogiannis S; Triantafyllou N; Gennimata V; Moulopoulou LE; Patsouris E; Nikou G; Michalaki V; Fragulidis G; Paphiti M; McCready RV; Colletti PM; Cook GJ; Rubello D
Clin Nucl Med; 2016 Mar; 41(3):194-200. PubMed ID: 26673241
[TBL] [Abstract][Full Text] [Related]
11. The addition of DTPA to [177Lu-DOTA0,Tyr3]octreotate prior to administration reduces rat skeleton uptake of radioactivity.
Breeman WA; van der Wansem K; Bernard BF; van Gameren A; Erion JL; Visser TJ; Krenning EP; de Jong M
Eur J Nucl Med Mol Imaging; 2003 Feb; 30(2):312-5. PubMed ID: 12552352
[TBL] [Abstract][Full Text] [Related]
12. Personalized
Del Prete M; Buteau FA; Beauregard JM
Eur J Nucl Med Mol Imaging; 2017 Aug; 44(9):1490-1500. PubMed ID: 28361189
[TBL] [Abstract][Full Text] [Related]
13. Biodistribution, Pharmacokinetics, and Dosimetry of
Nicolas GP; Mansi R; McDougall L; Kaufmann J; Bouterfa H; Wild D; Fani M
J Nucl Med; 2017 Sep; 58(9):1435-1441. PubMed ID: 28450554
[TBL] [Abstract][Full Text] [Related]
14. [177Lu-DOTA(0),Tyr3] octreotate for somatostatin receptor-targeted radionuclide therapy.
de Jong M; Breeman WA; Bernard BF; Bakker WH; Schaar M; van Gameren A; Bugaj JE; Erion J; Schmidt M; Srinivasan A; Krenning EP
Int J Cancer; 2001 Jun; 92(5):628-33. PubMed ID: 11340564
[TBL] [Abstract][Full Text] [Related]
15. Inhomogeneous activity distribution of 177Lu-DOTA0-Tyr3-octreotate and effects on somatostatin receptor expression in human carcinoid GOT1 tumors in nude mice.
Oddstig J; Bernhardt P; Lizana H; Nilsson O; Ahlman H; Kölby L; Forssell-Aronsson E
Tumour Biol; 2012 Feb; 33(1):229-39. PubMed ID: 22108870
[TBL] [Abstract][Full Text] [Related]
16. Minor changes in effective half-life during fractionated 177Lu-octreotate therapy.
Garske U; Sandström M; Johansson S; Sundin A; Granberg D; Eriksson B; Lundqvist H
Acta Oncol; 2012 Jan; 51(1):86-96. PubMed ID: 21961497
[TBL] [Abstract][Full Text] [Related]
17. Individualized dosimetry of kidney and bone marrow in patients undergoing 177Lu-DOTA-octreotate treatment.
Sandström M; Garske-Román U; Granberg D; Johansson S; Widström C; Eriksson B; Sundin A; Lundqvist H; Lubberink M
J Nucl Med; 2013 Jan; 54(1):33-41. PubMed ID: 23223392
[TBL] [Abstract][Full Text] [Related]
18. A comparison of (111)In-DOTATOC and (111)In-DOTATATE: biodistribution and dosimetry in the same patients with metastatic neuroendocrine tumours.
Forrer F; Uusijärvi H; Waldherr C; Cremonesi M; Bernhardt P; Mueller-Brand J; Maecke HR
Eur J Nucl Med Mol Imaging; 2004 Sep; 31(9):1257-62. PubMed ID: 15197500
[TBL] [Abstract][Full Text] [Related]
19. Effects of treatment with (177)Lu-DOTA-Tyr(3)-octreotate on uptake of subsequent injection in carcinoid-bearing nude mice.
Bernhardt P; Oddstig J; Kölby L; Nilsson O; Ahlman H; Forssell-Aronsson E
Cancer Biother Radiopharm; 2007 Oct; 22(5):644-53. PubMed ID: 17979567
[TBL] [Abstract][Full Text] [Related]
20. Biodistribution of 177Lu-octreotate and 111In-minigastrin in female nude mice transplanted with human medullary thyroid carcinoma GOT2.
Dalmo J; Rudqvist N; Spetz J; Laverman P; Nilsson O; Ahlman H; Forssell-Aronsson E
Oncol Rep; 2012 Jan; 27(1):174-81. PubMed ID: 21993546
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]